Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer

Abstract

The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, especially metastatic colorectal cancer comprising 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indo lino ne or a pharmaceutically acceptable salt thereof, and 2′-deoxy-5-(trifluoromethyl)uridine or a pharmaceutically acceptable salt thereof, and 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, wherein the molar ratio of 2′-deoxy-5-(trifluoromethyl)uridine or a pharmaceutically acceptable salt thereof, and 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, is 1:0.5

Dependencies are inferred from the claim text.